STOCK TITAN

Shattuck Labs, Inc. - $STTK STOCK NEWS

Welcome to our dedicated page for Shattuck Labs news (Ticker: $STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company at the forefront of developing innovative bi-functional fusion proteins. These unique proteins represent a new class of biologic medicine aimed at treating patients with cancer and autoimmune diseases. Shattuck's proprietary Agonist Redirected Checkpoint (ARC®) platform is designed to inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic, a groundbreaking approach in the biotechnology field.

The company's lead product candidate, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint and activate the CD40 pathway simultaneously. Currently, SL-172154 is in multiple Phase 1 clinical trials targeting various cancers, including platinum-resistant ovarian cancer and acute myeloid leukemia (AML). Another promising candidate, SL-279252 (PD1-Fc-OX40L), is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials.

Shattuck Labs recently embarked on an exciting collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. This partnership includes a significant financial package with potential milestone payments and royalties, reinforcing Shattuck's strong financial condition and innovative capabilities. Additionally, the company's proprietary gamma delta T cell engager platform, GADLEN™, promises to bridge gamma delta T cells to tumor antigens, offering new hope for cancer treatment.

Recent achievements include rapid enrollment in clinical trials and the FDA's orphan drug designation for SL-172154, highlighting the urgent need for new AML treatments. Shattuck is also actively participating in several high-profile conferences, sharing their latest research and clinical progress. The company is headquartered in Austin, Texas, and Durham, North Carolina, and continues to leverage its scientific expertise to address unmet medical needs.

  • Core Business: Development of bi-functional fusion proteins for cancer and autoimmune diseases.
  • Recent Achievements: FDA orphan drug designation for SL-172154, collaboration with Ono Pharmaceutical.
  • Current Projects: Phase 1 trials for SL-172154 and SL-279252, development of GADLEN™ platform.
  • Financial Condition: Strong financial backing with potential milestone payments from partnerships.
  • Partnerships: Collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.
Rhea-AI Summary

Shattuck Labs has revealed updated positive interim data from the Phase 1B clinical trial of SL-172154 combined with Azacitidine (AZA) for treating frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML).

The trial showed a 67% objective response rate (ORR) in HR-MDS patients, with a 58% complete remission rate, while frontline TP53m AML patients exhibited a 43% ORR and 33% complete remission with incomplete hematologic recovery.

SL-172154 demonstrated a manageable safety profile, with the most common adverse events being infusion-related reactions. The median overall survival for both patient groups has not yet been reached.

Shattuck is focusing on HR-MDS and TP53m AML due to competition and potential for accelerated approval pathways. The company will host a conference call on June 14, 2024, to discuss these findings further.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Shattuck Labs announced that its lead clinical candidate, SL-172154, has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of Acute Myeloid Leukemia (AML). This designation is awarded to drugs that address rare diseases affecting fewer than 200,000 people in the U.S. and provides benefits such as market exclusivity for seven years, tax credits for clinical trials, and waived application fees. The company plans to present additional data from the Phase 1B dose expansion clinical trial of SL-172154 at the European Hematology Association 2024 Congress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
-
Rhea-AI Summary

Shattuck Labs will host an investor call and webcast on June 14, 2024, at 7:30 a.m. ET to discuss additional interim data from their Phase 1B dose expansion clinical trial of SL-172154 combined with Azacitidine (AZA) in treating frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The event, held during the European Hematology Association (EHA) 2024 Congress, will feature lead investigator Dr. Naval G. Daver from The University of Texas MD Anderson Cancer Center. The webcast will provide updates on safety and efficacy from the ongoing trial. Participants must register in advance to join the webcast, and a replay will be available for those unable to attend the live session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
conferences clinical trial
Rhea-AI Summary

Shattuck Labs (Nasdaq: STTK) will present new data from its Phase 1B trial of SL-172154 at the European Hematology Association (EHA) 2024 Congress. The trial, which combines SL-172154 with azacitidine (AZA), targets frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML). As of February 1, 2024, the combination therapy showed promising complete response (CR) rates and an acceptable safety profile. The HR-MDS cohort had a 65% objective response rate (ORR), while TP53m AML had a 36% ORR. The next data update is expected in the second quarter of 2024. Key safety concerns include infusion-related reactions and some severe treatment-emergent adverse events (TEAEs).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
conferences clinical trial
-
Rhea-AI Summary

Shattuck Labs, Inc. (STTK) reported financial results for Q1 2024, highlighting progress in clinical trials for cancer treatments. They completed enrollment in Phase 1B cohorts for TP53m AML patients, presented preclinical data at AACR, and entered a collaboration with Ono Pharma. Financially, they have $114.6 million in cash and continue to focus on R&D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
-
Rhea-AI Summary
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.44%
Tags
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Dr. Taylor Schreiber, the CEO, will present on April 8, 2024, discussing the development of bi-functional fusion proteins for cancer and autoimmune disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
-
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) appoints Dr. Clay Siegall and Dr. Kate Sasser to its Board of Directors. Both bring valuable industry experience to lead late-stage clinical development of SL-172154, a promising new therapy for cancer and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
management
-
Rhea-AI Summary
Shattuck Labs, Inc. announced positive topline data from ongoing clinical trials of SL-172154 in combination with azacitidine in frontline HR-MDS and TP53m AML patients. The company completed enrollment in Phase 1B dose-expansion cohorts and entered into a collaboration with Ono Pharmaceutical Co. The financial results for Q4 2023 showed $130.6 million in cash and cash equivalents, with reduced R&D and G&A expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.54%
Tags
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) announced participation in investor conferences to discuss the development of bi-functional fusion proteins for cancer and autoimmune disease treatment. Key conferences include TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference 2024, and Citi's Biotech C-Suite Fireside Chat Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
none

FAQ

What is Shattuck Labs, Inc.'s core business?

Shattuck Labs focuses on developing bi-functional fusion proteins for cancer and autoimmune diseases.

What are the main product candidates of Shattuck Labs?

The main candidates are SL-172154 and SL-279252, both currently in Phase 1 clinical trials.

What is the ARC® platform?

The ARC® platform is Shattuck's proprietary technology designed to inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.

Who are Shattuck Labs' key partners?

Shattuck Labs has collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.

Where is Shattuck Labs headquartered?

Shattuck Labs is headquartered in Austin, Texas, and Durham, North Carolina.

What is SL-172154?

SL-172154 is an investigational ARC® fusion protein designed to block the CD47 immune checkpoint and activate the CD40 pathway for cancer treatment.

What recent achievements has Shattuck Labs made?

Recent achievements include the FDA orphan drug designation for SL-172154 and a collaboration with Ono Pharmaceutical.

What is the GADLEN™ platform?

The GADLEN™ platform is designed to bridge gamma delta T cells to tumor antigens, offering new treatment options for cancer.

What financial condition is Shattuck Labs in?

Shattuck Labs has a strong financial condition with potential milestone payments from partnerships.

What are some upcoming events for Shattuck Labs?

Shattuck Labs will participate in several high-profile conferences to share their latest research and clinical progress.

Shattuck Labs, Inc.

Nasdaq:STTK

STTK Rankings

STTK Stock Data

294.34M
30.26M
13.26%
59.85%
3.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
AUSTIN